Freeman Chris 4

What Happened Chris Freeman, Chief Commercial Officer of Guardant Health, had a tranche of restricted stock units (RSUs) vest on March 15, 2026. A total of 16,828 shares vested (15,426 + 1,402). The company converted the RSUs into common shares (reported as derivative conversions) and retained 7,127 of those shares to satisfy tax withholding obligations at a per-share value of $85.49, resulting in $609,287 withheld. The net shares issued to Freeman were 9,701 (16,828 − 7,127). The conversions were reported as acquired at $0.00 (typical for RSU vesting).

Key Details

• Transaction date: March 15, 2026; Form 4 filed March 17, 2026 (timely within the usual 2-business-day window).
• Shares vesting/converted: 16,828 total (15,426 and 1,402 reported separately).
• Tax withholding: 7,127 shares retained by the company at $85.49/share = $609,287 (coded F).
• Net shares delivered to insider: 9,701.
• Shares acquired at $0.00 reflect RSU vesting (coded M for conversion/exercise of derivative).
• Shares owned after transaction: Not disclosed in this filing.
• Footnotes: F2 = performance-based RSU (June 7, 2023 grant; second tranche metric achieved); F4 = time-based RSU (June 9, 2023 grant with scheduled installments); F1 = shares retained only to meet tax withholding, not in excess.

Context This was a compensation event (RSU vesting), not an open-market purchase or voluntary sale. The company’s retention of shares to cover tax withholding is a routine "sell-to-cover" mechanism and does not by itself indicate buying or selling sentiment by the insider. The filing shows conversion of RSU derivatives into shares and withholding for taxes rather than an exercise followed by an immediate market sale.